Galderma stock: Stronger guidance lifts Galderma stock 3.31 percent

Published on 10/23/2026 at 15:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guidance rose to 22.50-23.50 percent for 2026. Galderma stock costs EUR 204.50 on October 23, 2026, up 3.31 percent versus Tradegate.

Guidance and market position

Galderma raised 2026 net sales growth guidance to 22.50-23.50 percent on October 22, 2026.
Third-quarter 2026 net sales reached USD 1.632 billion, up 26.00 percent at constant currency.
Galderma stock costs EUR 204.50 at Lang & Schwarz on October 23, 2026 at 3:30 p.m. CEST, 3.31 percent above the Tradegate close of October 22, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma Group AG stock (ISIN CH1335392721) was trading at EUR 204.50 at Lang & Schwarz on October 23, 2026 at 3:30 p.m. CEST, up 3.31 percent versus the Tradegate close of October 22, 2026 at EUR 197.95. The company raised its 2026 net sales growth guidance after third-quarter results, according to Finanznachrichten on October 22, 2026.

Guidance moves higher

Galderma lifted its full-year 2026 net sales growth outlook to 22.50-23.50 percent at constant currency from 19.00-21.00 percent previously. The company also confirmed its Core EBITDA margin outlook at 26.00 percent at constant currency, according to the same October 22 release.

Third-quarter 2026 net sales rose 26.00 percent at constant currency to USD 1.632 billion from USD 1.289 billion in the third quarter of 2025. For the first nine months of 2026, sales reached USD 4.765 billion, up 25.10 percent at constant currency from USD 3.737 billion in the comparable period.

Stock position and valuation

On SIX, Galderma was trading at CHF 189.00 on October 23, 2026 at 3:15 p.m. CEST. Its 52-week range was CHF 136.30 to CHF 189.70, while market capitalization stood at CHF 44.1 billion and the price-to-earnings ratio at 63.00.

The current SIX price sits 0.37 percent below the 52-week high. The Swiss Market Index inclusion on September 21, 2026 added a new index reference to the company profile, while the stronger sales outlook remains the latest operating figure.

What comes next for Galderma?

Galderma expects the proposed USD 1.5 billion acquisition of ZO Skin Health to close in the fourth quarter of 2026 or early 2027, subject to approvals. The company is targeting the first quarter of 2027 to resubmit its US application for Relfydess, according to the October 22 release.

Yahoo Finance reported on October 22, 2026 that Jefferies retained a Buy rating and a CHF 205.00 price target. That target lies 8.47 percent above the SIX price of CHF 189.00.

Price after the guidance update

Galderma stock was trading at EUR 204.50 at Lang & Schwarz on October 23, 2026 at 3:30 p.m. CEST, 3.31 percent above the Tradegate close of October 22, 2026 at EUR 197.95. The further course of trading is shown by the continuously updated real-time quote of Galderma stock.